주사용 약물전달 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of injectable drug delivery Market

The global injectable drug delivery market is experiencing strong growth due to the increasing prevalence of chronic diseases, rising demand for convenient drug administration, and rapid development of advanced injection technologies. The global injectable drug delivery market size was valued at USD 756.22 billion in 2025. The market is projected to grow from USD 828.51 billion in 2026 to USD 1,719.94 billion by 2034, exhibiting a CAGR of 9.56% during 2026-2034. North America dominated the market with a 22.83% share in 2025, supported by advanced healthcare infrastructure and widespread adoption of innovative drug delivery technologies.

Injectable drug delivery systems enable medicines to be administered efficiently and directly into the body. The market includes conventional injectables as well as technologically advanced systems such as pre-filled syringes, auto-injectors, pen-injectors, and wearable devices. Increasing demand for self-administration, minimally invasive treatment, and patient-friendly delivery solutions is creating significant opportunities for manufacturers.

Market Definition and Scope

Injectable drug delivery refers to systems and devices used to administer therapeutic drugs through injection. These technologies are increasingly replacing conventional vial-and-syringe approaches with convenient and ready-to-use solutions. Pre-filled syringes, auto-injectors, pen-injectors, and wearable injectors help improve dosing accuracy, treatment convenience, and patient compliance.

The market covers device types, product types, end users, and regional markets, with applications across hospitals, clinics, homecare settings, and other healthcare environments. Growing demand for advanced therapies and self-administration devices is further expanding the market scope.

Market Dynamics

Drivers

The rising patient preference for ready-to-use and reusable injectable devices is a major market driver. Conventional vial-and-syringe systems can involve dosing and handling errors and may increase infection risks. Pre-filled syringes and other advanced devices offer greater convenience, accuracy, and ease of use.

Continuous research and development in drug delivery technologies is also supporting market expansion. Manufacturers are developing smart wearables, needle-free injectors, advanced syringes, and connected devices to improve treatment delivery. Increasing prevalence of diabetes, cancer, autoimmune disorders, and other chronic diseases is further increasing demand.

Trends

Strong mergers, acquisitions, and strategic partnerships are contributing to product innovation. Pharmaceutical and medical device companies are increasingly focusing on sterile packaging, pre-filled systems, wearable injectors, and convenient drug delivery technologies.

The growing adoption of wearable and self-administration devices is another important trend, particularly as patients increasingly seek convenient treatment options outside hospitals and clinics.

Restraints

The high cost of advanced injectable devices and active therapies can limit adoption, particularly in emerging economies. Limited reimbursement coverage and high out-of-pocket healthcare expenditure also encourage patients to continue using traditional injectable products rather than advanced delivery systems.

Impact of COVID-19

COVID-19 created both opportunities and challenges for the injectable drug delivery market. Increased demand for injections, pre-filled syringes, and medical supplies encouraged manufacturers to increase production capacity. Supply-chain disruptions affected certain systems, while the pandemic also accelerated research into smart wearables and technologies supporting remote healthcare and patient monitoring.

Segmentation Analysis

By device type, the market includes conventional injectables, pre-filled syringes, auto-injectors, pen-injectors, and wearable devices. Conventional injectables held the largest market share in 2025, supported by widespread use in hospitals, surgeries, infectious disease treatment, and immunization programs.

By product type, the market is divided into freeze-dried products and injectable sterile products. Injectable sterile products dominated the market due to their quality, storability, and lower infection risk. Freeze-dried products are expected to witness faster growth because they support drug stability and bioavailability.

By end user, the market includes hospitals, clinics, homecare settings, and others. Hospitals remain dominant, while homecare settings are expected to experience significant growth as patients increasingly shift toward convenient treatment at home.

Regional Insights

North America dominated the market with a regional value of USD 172.67 billion in 2025, supported by advanced healthcare infrastructure, strong regulatory frameworks, chronic disease prevalence, and adoption of self-administration technologies.

Europe represented a significant market share due to established healthcare infrastructure, biologics adoption, and growing demand for patient-centric injectable solutions.

Asia Pacific is projected to register the highest growth rate, driven by increasing healthcare expenditure, expanding patient populations, improved healthcare access, and growing adoption of advanced injectable systems.

Latin America is witnessing steady development as healthcare infrastructure improves and access to advanced therapies expands.

Middle East & Africa offer growth opportunities through healthcare modernization, increasing healthcare expenditure, and expanding specialized treatment facilities.

Competitive Landscape

The market is competitive, with major companies focusing on advanced products, strong distribution networks, and innovative drug delivery technologies. Key players include BD, SHL Medical AG, Schott AG, West Pharmaceutical Services, Pfizer Inc., Insulet Corporation, Elcam Medical, Eli Lilly and Company, Ypsomed AG, Gerresheimer AG, and Baxter International Inc.

Key Industry Developments

Major developments include BD's successful clinical trial of the BD Libertas Wearable Injector, TEVA's launch of the AJOVY auto-injector, BD's launch of the BD Intevia two-step disposable auto-injector, and Hikma Pharmaceuticals' launch of new pre-fillable syringes in the U.S.

Report Coverage

The report provides comprehensive analysis of the injectable drug delivery market, covering market size, market value, device types, product types, end users, regional markets, market trends, growth drivers, restraints, competitive landscape, and key industry developments. It also evaluates technological innovations and factors influencing the adoption of advanced injectable drug delivery systems.

Conclusion

The global injectable drug delivery market is projected to expand from USD 756.22 billion in 2025 to USD 828.51 billion in 2026 and reach USD 1,719.94 billion by 2034. Rising chronic disease prevalence, increasing patient preference for convenient self-administration, continuous R&D, and growing adoption of pre-filled, wearable, and smart injectable devices will support long-term market growth. North America remains a leading market, while Asia Pacific is expected to provide significant future growth opportunities.

Unit Value (USD Billion)

By Device Type

• Conventional Injectable
• Pre-filled Syringes
• Auto-injectors
• Pen-injectors
• Wearable

By Product Type

• Freeze-dried Products
• Injectable Sterile Products

By End User

• Hospitals
• Home Care Settings
• Clinics
• Others

By Geography

• North America (the USA, and Canada)
• Europe (UK, Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)
• Latin America (Brazil, Mexico and the Rest of the Latin America)
• Middle East & Africa (South Africa, GCC and the Rest of the Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Market Scope
• 1.2. Market Segmentation
• 1.3. Market Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence of Key Diseases - For Key Countries, 2025
• 4.2. New Product Launch
• 4.3. Overview of Technological Advancements In Injectable Drug Delivery Devices
• 4.4. Key Industry Developments - Mergers, Acquisitions, and Partnerships

5. Global Injectable Drug Delivery Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Device Type
  • 5.2.1. Conventional Injectables
  • 5.2.2. Pre-filled Syringes
  • 5.2.3. Auto-injectors
  • 5.2.4. Pen-injectors
  • 5.2.5. Wearable
• 5.3. Market Analysis, Insights and Forecast - By Product Type
  • 5.3.1. Freeze-dried Products
  • 5.3.2. Injectable Sterile Products
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Hospitals
  • 5.4.2. Homecare Settings
  • 5.4.3. Clinics
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - By Geography
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Injectable Drug Delivery Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis, Insights and Forecast - By Device Type
  • 6.2.1. Conventional Injectables
  • 6.2.2. Pre-filled Syringes
  • 6.2.3. Auto-injectors
  • 6.2.4. Pen-injectors
  • 6.2.5. Wearable
• 6.3. Market Analysis, Insights and Forecast - By Product Type
  • 6.3.1. Freeze-dried Products
  • 6.3.2. Injectable Sterile Products
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Hospitals
  • 6.4.2. Homecare Settings
  • 6.4.3. Clinics
  • 6.4.4. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Injectable Drug Delivery Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis, Insights and Forecast - By Device Type
  • 7.2.1. Conventional Injectables
  • 7.2.2. Pre-filled Syringes
  • 7.2.3. Auto-injectors
  • 7.2.4. Pen-injectors
  • 7.2.5. Wearable
• 7.3. Market Analysis, Insights and Forecast - By Product Type
  • 7.3.1. Freeze-dried Products
  • 7.3.2. Injectable Sterile Products
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Hospitals
  • 7.4.2. Homecare Settings
  • 7.4.3. Clinics
  • 7.4.4. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Injectable Drug Delivery Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis, Insights and Forecast - By Device Type
  • 8.2.1. Conventional Injectables
  • 8.2.2. Pre-filled Syringes
  • 8.2.3. Auto-injectors
  • 8.2.4. Pen-injectors
  • 8.2.5. Wearable
• 8.3. Market Analysis, Insights and Forecast - By Product Type
  • 8.3.1. Freeze-dried Products
  • 8.3.2. Injectable Sterile Products
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Hospitals
  • 8.4.2. Homecare Settings
  • 8.4.3. Clinics
  • 8.4.4. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Injectable Drug Delivery Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis, Insights and Forecast - By Device Type
  • 9.2.1. Conventional Injectables
  • 9.2.2. Pre-filled Syringes
  • 9.2.3. Auto-injectors
  • 9.2.4. Pen-injectors
  • 9.2.5. Wearable
• 9.3. Market Analysis, Insights and Forecast - By Product Type
  • 9.3.1. Freeze-dried Products
  • 9.3.2. Injectable Sterile Products
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Hospitals
  • 9.4.2. Homecare Settings
  • 9.4.3. Clinics
  • 9.4.4. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Injectable Drug Delivery Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis, Insights and Forecast - By Device Type
  • 10.2.1. Conventional Injectables
  • 10.2.2. Pre-filled Syringes
  • 10.2.3. Auto-injectors
  • 10.2.4. Pen-injectors
  • 10.2.5. Wearable
• 10.3. Market Analysis, Insights and Forecast - By Product Type
  • 10.3.1. Freeze-dried Products
  • 10.3.2. Injectable Sterile Products
• 10.4. Market Analysis, Insights and Forecast - By End User
  • 10.4.1. Hospitals
  • 10.4.2. Homecare Settings
  • 10.4.3. Clinics
  • 10.4.4. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Competition Dashboard
• 11.4. Comparative Analysis - Major Players
• 11.5. Company Profiles
  • 11.5.1. BD
    • 11.5.1.1. Overview,
    • 11.5.1.2. Product Type& Services,
    • 11.5.1.3. SWOT Analysis,
    • 11.5.1.4. Recent Developments,
    • 11.5.1.5. Strategies,
    • 11.5.1.6. Financials (Based on Availability)
  • 11.5.2. SHL Group
    • 11.5.2.1. Overview,
    • 11.5.2.2. Product Type& Services,
    • 11.5.2.3. SWOT Analysis,
    • 11.5.2.4. Recent Developments,
    • 11.5.2.5. Strategies,
    • 11.5.2.6. Financials (Based on Availability)
  • 11.5.3. Schott AG
    • 11.5.3.1. Overview,
    • 11.5.3.2. Product Type& Services,
    • 11.5.3.3. SWOT Analysis,
    • 11.5.3.4. Recent Developments,
    • 11.5.3.5. Strategies,
    • 11.5.3.6. Financials (Based on Availability)
  • 11.5.4. West Pharmaceutical Services, Inc.
    • 11.5.4.1. Overview,
    • 11.5.4.2. Product Type& Services,
    • 11.5.4.3. SWOT Analysis,
    • 11.5.4.4. Recent Developments,
    • 11.5.4.5. Strategies,
    • 11.5.4.6. Financials (Based on Availability)
  • 11.5.5. Pfizer Inc.
    • 11.5.5.1. Overview,
    • 11.5.5.2. Product Type& Services,
    • 11.5.5.3. SWOT Analysis,
    • 11.5.5.4. Recent Developments,
    • 11.5.5.5. Strategies,
    • 11.5.5.6. Financials (Based on Availability)
  • 11.5.6. Insulet Corporation
    • 11.5.6.1. Overview,
    • 11.5.6.2. Product Type& Services,
    • 11.5.6.3. SWOT Analysis,
    • 11.5.6.4. Recent Developments,
    • 11.5.6.5. Strategies,
    • 11.5.6.6. Financials (Based on Availability)
  • 11.5.7. Elcam Medical
    • 11.5.7.1. Overview,
    • 11.5.7.2. Product Type& Services,
    • 11.5.7.3. SWOT Analysis,
    • 11.5.7.4. Recent Developments,
    • 11.5.7.5. Strategies,
    • 11.5.7.6. Financials (Based on Availability)
  • 11.5.8. Eli Lilly and Company
    • 11.5.8.1. Overview,
    • 11.5.8.2. Product Type& Services,
    • 11.5.8.3. SWOT Analysis,
    • 11.5.8.4. Recent Developments,
    • 11.5.8.5. Strategies,
    • 11.5.8.6. Financials (Based on Availability)
  • 11.5.9. West Pharmaceutical Services, Inc.
    • 11.5.9.1. Overview,
    • 11.5.9.2. Product Type& Services,
    • 11.5.9.3. SWOT Analysis,
    • 11.5.9.4. Recent Developments,
    • 11.5.9.5. Strategies,
    • 11.5.9.6. Financials (Based on Availability)
  • 11.5.10. Ypsomed AG
    • 11.5.10.1. Overview,
    • 11.5.10.2. Product Type& Services,
    • 11.5.10.3. SWOT Analysis,
    • 11.5.10.4. Recent Developments,
    • 11.5.10.5. Strategies,
    • 11.5.10.6. Financials (Based on Availability)
  • 11.5.11. Gerresheimer AG
    • 11.5.11.1. Overview,
    • 11.5.11.2. Product Type& Services,
    • 11.5.11.3. SWOT Analysis,
    • 11.5.11.4. Recent Developments,
    • 11.5.11.5. Strategies,
    • 11.5.11.6. Financials (Based on Availability)
  • 11.5.12. Baxter International Inc
    • 11.5.12.1. Overview,
    • 11.5.12.2. Product Type& Services,
    • 11.5.12.3. SWOT Analysis,
    • 11.5.12.4. Recent Developments,
    • 11.5.12.5. Strategies,
    • 11.5.12.6. Financials (Based on Availability)
  • 11.5.13. Other Prominent Players
    • 11.5.13.1. Overview,
    • 11.5.13.2. Product Type& Services,
    • 11.5.13.3. SWOT Analysis,
    • 11.5.13.4. Recent Developments,
    • 11.5.13.5. Strategies,
    • 11.5.13.6. Financials (Based on Availability)

12. Strategic Recommendations